Incyte Corp
(BSP:I1NC34)
R$
221.1
0 (0%)
Market Cap: 85.19 Bil
Enterprise Value: 74.99 Bil
PE Ratio: 552.00
PB Ratio: 4.70
GF Score: 77/100 
Incyte Corp at Wells Fargo Healthcare Conference Transcript
Sep 07, 2023 / 12:45PM GMT
Release Date Price:
R$160.02
Derek Christian Archila
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
All right. Good morning, everyone. We'll get started with the next fireside discussion. My name is Derek Archila. I'm one of the senior biotech analysts here at Wells. Very excited to have with us for the next discussion, Incyte. From the company, we have the Chairman and CEO, Herve Hoppenot; and also the CFO, Christiana Stamoulis. Thank you so much for joining us.
Herve Hoppenot
Incyte Corporation - CEO & Chairman
Good morning. Thank you for inviting us.
Derek Christian Archila
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
Yes. Well, look forward to the discussion.
Questions & Answers
Derek Christian Archila
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
But maybe, Herve, if you want to just start by kind of giving us kind of a state of the business, where you guys are and what you guys are executing on, and
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers